Senior Research Statistician
Modelling incremental benefits on complications rates when targeting lower HbA1clevels in people with Type 2 diabetes and cardiovascular disease.
Mostafa SA. et al, (2018), Diabet Med, 35, 72 - 77
Health selection into neighborhoods among patients enrolled in a clinical trial.
Arcaya MC. et al, (2017), Prev Med Rep, 8, 51 - 54
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR. et al, (2017), Lancet Diabetes Endocrinol, 5, 877 - 886
Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.
Malhotra R. et al, (2017), JAMA Intern Med, 177, 1498 - 1505
Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
Agbaje OF. et al, (2017), DIABETOLOGIA, 60, S300 - S300